BTIG maintains Buy rating on ArriVent BioPharma; $29 target
BTIG reiterated its Buy rating on ArriVent BioPharma and kept its $29.00 price target, implying 92.2% upside versus the Oct. 6 close of $15.09.
BTIG reiterated its Buy rating on ArriVent BioPharma and kept its $29.00 price target, implying 92.2% upside versus the Oct. 6 close of $15.09.